

# Kourosh Lotfi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/381683/publications.pdf>

Version: 2024-02-01

18  
papers

271  
citations

933447

10  
h-index

996975

15  
g-index

21  
all docs

21  
docs citations

21  
times ranked

527  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance. <i>Cancer Letters</i> , 2002, 178, 141-149.	7.2	54
2	Pharmacological Basis for Cladribine Resistance. <i>Leukemia and Lymphoma</i> , 2003, 44, 1705-1712.	1.3	36
3	Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells. <i>Blood</i> , 2014, 124, 812-812.	1.4	33
4	Glucose starvation-mediated inhibition of salinomycin induced autophagy amplifies cancer cell specific cell death. <i>Oncotarget</i> , 2015, 6, 10134-10145.	1.8	25
5	The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia. <i>Biochemical Pharmacology</i> , 2006, 71, 882-890.	4.4	21
6	Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1543-1554.	2.5	20
7	Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. <i>Oncolmmunology</i> , 2019, 8, e1638210.	4.6	19
8	Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 183-193.	2.3	16
9	Varying effects of tyrosine kinase inhibitors on platelet functionâ€”A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?. <i>Cancer Medicine</i> , 2020, 9, 313-323.	2.8	16
10	Spontaneous Reversal of P-Glycoprotein Expression in Multidrug Resistant Cell Lines*. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2003, 93, 297-304.	0.0	10
11	Single Nucleotide Polymorphisms in MORC4, CD14, and TLR4 Are Related to Outcome of Allogeneic Stem Cell Transplantation. <i>Annals of Transplantation</i> , 2016, 21, 56-67.	0.9	10
12	Multiplexed singleâ€”cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells. <i>Experimental Hematology and Oncology</i> , 2021, 10, 7.	5.0	4
13	Mature, Adaptive-like CD56DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission. <i>Blood</i> , 2015, 126, 343-343.	1.4	3
14	Single-Cell RNA Sequencing of Hematopoietic Stem and Progenitor Cells Treated with Gemcitabine and Carboplatin. <i>Genes</i> , 2020, 11, 549.	2.4	2
15	Sensitivity of Acute Myelocytic Leukemia Cells to the Dienone Compound VLX1570 Is Associated with Inhibition of the Ubiquitin-Proteasome System. <i>Biomolecules</i> , 2021, 11, 1339.	4.0	2
16	Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study. <i>Bone Marrow Transplantation</i> , 2021, 56, 807-817.	2.4	0
17	The Expression of mRNA and Enzyme Activity of Deoxycytidine- and Deoxyguanosine Kinases in Cell from Patients with Untreated B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004, 104, 4378-4378.	1.4	0
18	Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment. <i>Blood</i> , 2016, 128, 3069-3069.	1.4	0